Diversity Supplement: Targeting chemoresistant prostate cancer with novel EED inhibitors

NIH RePORTER · NIH · R01 · $59,167 · view on reporter.nih.gov ↗

Abstract

This Diversity Supplement will train Ms. Skylar Grayson, a highly qualified African American researcher, in cancer research and prepare her for a doctoral program in biological sciences, clinical pharmacology, or toxicology. Ms. Grayson will participate in the Specific Aims 2 and 3 as outlined in the parent grant, specifically, evaluating the in vitro and in vivo activities of new EED inhibitors against chemoresistant PCa in preclinical models and determining the drug-like properties and toxicology of lead compounds. We will provide a candidate-specific training environment to maximize Ms. Grayson’s potential as a graduate student in pharmacology or toxicology.

Key facts

NIH application ID
10747516
Project number
3R01CA256058-02S1
Recipient
CLARK ATLANTA UNIVERSITY
Principal Investigator
DAQING WU
Activity code
R01
Funding institute
NIH
Fiscal year
2023
Award amount
$59,167
Award type
3
Project period
2022-04-01 → 2027-03-31